Tumor-specific TCRα and TCRβ sequencing demonstrated that the CD8+ cells from tumors or tdLNs of BF10-treated mice harbored the highest clonotype diversity compared with the other groups, whereas IL-10-Fc treatment increased the diversity of the TCR repertoire of CD8+ cells from spleen (Figures 5K and S9F). This evidence concerns the gene IL10 and neoplasm.